| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10350186 | FRESENIUS KABI USA | Treatment and prevention of liver disease associated with parenteral nutrition (PN) |
Nov, 2024
(6 months from now) | |
| US9629821 | FRESENIUS KABI USA | Treatment and prevention of liver disease associated with parenteral nutrition (PN) |
Jul, 2025
(1 year, 2 months from now) | |
| US9566260 | FRESENIUS KABI USA | Treatment and prevention of liver disease associated with parenteral nutrition (PN) |
Jul, 2025
(1 year, 2 months from now) | |
Omegaven is owned by Fresenius Kabi Usa.
Omegaven contains Fish Oil Triglycerides.
Omegaven has a total of 3 drug patents out of which 0 drug patents have expired.
Omegaven was authorised for market use on 27 July, 2018.
Omegaven is available in emulsion;intravenous dosage forms.
Omegaven can be used as treatment of parenteral nutrition-associated cholestasis in patients under the age of 12, treatment of liver disease through nutrition for patients under the age of 12, use for patients with parenteral nutrition associated cholestasis or parenteral nutrition associated liver disease.
Drug patent challenges can be filed against Omegaven from 27 July, 2022.
The generics of Omegaven are possible to be released after 27 July, 2025.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-202) | Jul 27, 2025 |
| New Chemical Entity Exclusivity(NCE) | Jul 27, 2023 |
Drugs and Companies using FISH OIL TRIGLYCERIDES ingredient
NCE-1 date: 27 July, 2022
Market Authorisation Date: 27 July, 2018
Treatment: Treatment of parenteral nutrition-associated cholestasis in patients under the age of 12; Use for patients with parenteral nutrition associated cholestasis or parenteral nutrition associated liver dis...
Dosage: EMULSION;INTRAVENOUS
OMEGAVEN family patents
